About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ABUS
- Previous Close: $2.70
- 50 Day Moving Average: $2.66
- 200 Day Moving Average: $3.09
- 52-Week Range: $2.35 - $5.48
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.53
- P/E Growth: 0.00
- Market Cap: $142.59M
- Outstanding Shares: 54,841,000
- Beta: 1.24
- Net Margins: -1,192.92%
- Return on Equity: -8.50%
- Return on Assets: -6.68%
Companies Related to Arbutus Biopharma Corp:
- Current Ratio: 18.09%
- Quick Ratio: 18.09%
What is Arbutus Biopharma Corp's stock symbol?
Arbutus Biopharma Corp trades on the NASDAQ under the ticker symbol "ABUS."
Where is Arbutus Biopharma Corp's stock going? Where will Arbutus Biopharma Corp's stock price be in 2017?
6 analysts have issued 12-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $3.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $6.25 in the next twelve months.
When will Arbutus Biopharma Corp announce their earnings?
Arbutus Biopharma Corp is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
What are analysts saying about Arbutus Biopharma Corp stock?
Here are some recent quotes from research analysts about Arbutus Biopharma Corp stock:
According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (2/17/2017)
- Wedbush analysts commented, "We see ABUS as well positioned with data from three clinical assets set to provide positive news-flow in 2017. We believe recently presented preclinical data demonstrating synergy of these assets support ABUS's strategy of an effective combination therapy for HBV. We also see additional upside to shares from the mid:17 readout of Alnylam's (ALNY, not covered) Ph 3 study of patisiran, as well as the potential for additional partnerships around ABUS's attractive LNP platform." (1/31/2017)
Who owns Arbutus Biopharma Corp stock?
Arbutus Biopharma Corp's stock is owned by a number of of institutional and retail investors. Top institutional investors include Ladenburg Thalmann Financial Services Inc. (9.66%), Armistice Capital LLC (3.54%), Falcon Edge Capital LP (3.02%) and Oxford Asset Management (0.29%).
Who sold Arbutus Biopharma Corp stock? Who is selling Arbutus Biopharma Corp stock?
Arbutus Biopharma Corp's stock was sold by a variety of institutional investors in the last quarter, including Falcon Edge Capital LP.
Who bought Arbutus Biopharma Corp stock? Who is buying Arbutus Biopharma Corp stock?
Arbutus Biopharma Corp's stock was purchased by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc., Armistice Capital LLC and Oxford Asset Management.
How do I buy Arbutus Biopharma Corp stock?
Shares of Arbutus Biopharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Arbutus Biopharma Corp stock cost?
One share of Arbutus Biopharma Corp stock can currently be purchased for approximately $2.60.